Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128204 | 1.00 | MEN1 (0.45) | MEN1KMT2ADRD4PPARAMDM2 | |
| SCHEMBL19712373 | 0.88 | MEN1 (0.39) | MEN1KMT2ADRD4PPARAMDM2 | |
| SCHEMBL2129056 | 0.87 | MEN1 (0.45) | MEN1KMT2ADRD4PPARAMDM2 | |
| SCHEMBL2131268 | 0.86 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL30795446 | 0.86 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL2128658 | 0.85 | MEN1 (0.43) | MEN1KMT2ADRD4PPARACYP2C9 | |
| SCHEMBL2130019 | 0.85 | MEN1 (0.43) | MEN1KMT2ADRD4PPARACYP2C9 | |
| SCHEMBL19712383 | 0.78 | MDM2 (0.39) | MEN1KMT2ADRD4PPARAMDM2 | |
| SCHEMBL2130332 | 0.78 | AKT1 (0.46) | MEN1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL30794392 | 0.78 | AKT1 (0.46) | MEN1KMT2ASMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |